Equity Overview
Price & Market Data
Price: $5.22
Daily Change: -$0.51 / 9.77%
Daily Range: $4.95 - $6.11
Market Cap: $245,238,272
Daily Volume: 211,468
Performance Metrics
1 Week: -20.73%
1 Month: 91.24%
3 Months: -88.69%
6 Months: -88.69%
1 Year: -88.69%
YTD: -85.03%
Company Details
Employees: 11
Sector: Commercial services
Industry: Miscellaneous commercial services
Country: United States
Details
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.